On Jun, 29 Acasti Pharma Inc. (ACST) Sets 1 Year Low at $0.64

June 29, 2018 - By Matthew Medley

Acasti Pharma Inc. (NASDAQ:ACST) Corporate Logo

Acasti Pharma Inc. (NASDAQ:ACST) touched 1-year low touching $0.64. Our target is $0.59. Barchart.com reported the 1-year low on Jun, 29. Acasti Pharma Inc. (NASDAQ:ACST) has $25.26 million MC. At our $0.59 target, the company worth will be $2.02M less.

ACST hit $0.6397 during the last trading session after $0.0118 change.Currently Acasti Pharma Inc. is downtrending after 43.65% change in last June 29, 2017. ACST has 42,057 shares volume. The stock underperformed the S&P500 by 56.22%.

For more Acasti Pharma Inc. (NASDAQ:ACST) news posted recently go to: Streetinsider.com, Nasdaq.com, Benzinga.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Form 6-K Acasti Pharma Inc. For: Jun 04” posted on June 05, 2018, “Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018” on June 27, 2018, “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” with a publish date: June 28, 2018, “Acasti Pharma Appoints Brian Groch as Chief Commercial Officer” and the last “Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis” with publication date: June 06, 2018.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.The company has $25.26 million market cap. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia.Currently it has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.